Biocryst Pharmaceuticals Stock
Price
Target price
€5.68
€5.68
1.070%
0.062
1.070%
€11.05
20.05.24 / Tradegate
WKN: 896047 / Symbol: BCRX / Name: Biocryst Pharm / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Biocryst Pharmaceuticals Stock
Biocryst Pharmaceuticals gained 1.070% today.
Biocryst Pharmaceuticals is currently one of the favorites of our community with 9 Buy predictions and no Sell predictions.
With a target price of 11 € there is a hugely positive potential of 93.8% for Biocryst Pharmaceuticals compared to the current price of 5.68 €.
So far the community has only identified positive things for Biocryst Pharmaceuticals stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Biocryst Pharmaceuticals in the next few years
Pros
?
M***** P*******
?
G***** c******* t* c**********
?
B****
Cons
?
W********* I********* f** t** n*** y****
?
S********** s********
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Biocryst Pharmaceuticals vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Biocryst Pharmaceuticals | 1.070% | 16.950% | 38.890% | -25.929% | 4.481% | -49.678% | -12.961% |
| Ardelyx Inc. | -0.830% | -0.416% | 17.913% | 119.146% | 24.360% | 27.221% | - |
| Evolus Inc | 5.130% | 4.237% | 16.038% | 36.667% | 35.912% | 72.028% | - |
| Salarius Pharmaceuticals Inc. | 0.970% | -5.069% | -1.905% | -64.174% | -25.766% | -98.542% | -99.992% |
Comments
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.
Show more
Ratings data for BCRX provided by MarketBeat
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $12.00 price target on the stock.
Show more
Ratings data for BCRX provided by MarketBeat
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $12.00 price target on the stock.
Show more
Ratings data for BCRX provided by MarketBeat